dreamydays
Senior Member
- Messages
- 182
- Location
- United Kingdom
Ok brave people. In Montoyas new lecture he posits the use of the drug tofacitinib (Xeljanz). This is in relation to the general cytokine behavour found in severe patients. I have already found a supplier and its aviailable from India and Turkey at around £450 per month. I feel like this would be a short term treatment if I were to try it as I have been at all levels of ME, very mild to bebdound. So I feel if it pushed me up a level I would stop the treatment and try and sustain it. Does this drug fit in with anyones current thinking of the mechanism of our disease?